易瑞生物(300942) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of between 15 million and 22 million yuan for 2024, compared to a loss of 184.91 million yuan in the same period last year[4]. - The net profit after deducting non-recurring gains and losses is projected to range from a loss of 5 million yuan to a profit of 2 million yuan, compared to a loss of 193.91 million yuan in the previous year[4]. - Non-recurring gains and losses are expected to impact net profit by approximately 18 million to 22 million yuan, primarily from government subsidies and investment income[7]. - The financial data presented is preliminary and subject to change upon final audit, with detailed figures to be disclosed in the 2024 annual report[8]. Business Strategy - The company has focused on its core business in food safety rapid testing and animal diagnostics, achieving revenue growth in both segments[6]. - International market expansion efforts have resulted in increased sales scale year-on-year, supported by investments in personnel, channel development, and product certification[6]. - The company has reduced costs significantly after strategically downsizing its in vitro diagnostics business, leading to improved profitability[7]. - The company is enhancing its market competitiveness by deepening its business layout in the food safety sector and investing in animal diagnostics and intelligent instruments[7].